Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

alvimopan

alvimopan
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Entereg CAPSULE, ORAL 12 mg      
VIEW MORE GI Drugs, Miscellaneous
CLASS
569200
Comments:

Alvimopan (Entereg) Protocol - Recommend discontinuation to prescriber after patient's first bowel movement. Automatic stop after a total of 15 doses (7 days), or at the time of discharge, whichever occurs first.

Alvimopan is for short term hospital use only and limited to a total of 15 doses (14 doses post-op), should not be used in outpatient setting.

 
 
 
Drug Transfer to Another Hospital -  Alvimopan should not be transferred to any other hospital that is not alvimopan REMS certified.  
 
 

Alvimopan REMS Approved Prescriber List

Alvimopan – Formulary restricted to patients with partial large/small bowel disease undergoing bowel resection, or patients undergoing radical cystectomy restricted to physicians who are abdominal surgeons, gastroenterologists, or urologists approved in the REMS program per HH physician specific education (see REMS program approved physicians under Rx for Nursing or Rx for Physicians). 

 

 

Reviewed: September 23, 2008 and 28 Feb 2017 (discontinuation rules)

Updated: June 2021 (automatic discontinuation discontinued)

REMS: View FDA REMS Info

Last updated: Sep. 6, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved